Status:
UNKNOWN
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
Lead Sponsor:
An-Najah National University
Conditions:
Contrast-induced Nephropathy
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Contrast induced nephropathy (CIN) is a well-known possible complication of percutaneous coronary intervention (PCI) with an incidence varies from 3.3% to 14.5% in patients undergoing PCI. Many previ...
Detailed Description
The study design is a Randomized Control Trial; it will be done on two groups of patients. The two groups are group A (continue ACE-I/ARBs) and group B (withhold ACE-I/ARBs). The study will be conduc...
Eligibility Criteria
Inclusion
- At least one month of continuous therapy with an ACEI or an ARBs and
- Undergoing elective coronary angiography and
- Have CKD stage3-4 (15≤GFR\<60 ml/min/1.73 m2).
Exclusion
- Acute STEMI within 2 weeks
- NYHA class IV heart failure by history
- Administration of contrast load within the previous 6 days
- acute renal failure (ARF) preceding coronary angiography
- potassium level more than 5.0 meq/l
- GFR \<15 ml/min/1.73 m2
- previous percutaneous cardiac catheterization within one month
- Acute pulmonary edema
- hemodynamically instability
- uncontrolled hypertension
- combination ACEI and ARB therapy
- Cardiogenic shock
- Sepsis
- pregnancy
- Age below 18 year
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05271448
Start Date
June 1 2021
End Date
August 1 2024
Last Update
June 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
An-Najah National University Hospital
Nablus, West Bank, Palestinian Territories, P4170051